Clinical relevance of the urokinase plasminogen activator system in breast cancer

APMIS

Volumn 107, Issue 1, 1999, Pages 150-159

  Look, Maxime P ^a,b   Foekens, John A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Breast cancer; PAI 1; PAI 2; uPA; uPAR

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RECEPTOR DENSITY; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME;

EID: 0033003666     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01538.x     Document Type: Review

References (50)

1. 1. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
2. 2. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24.
3. 3. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Ballière Clin Heamatol 1995;2:365-89.
4. 4. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Throm Haemost 1997;78:285-96.
5. 5. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
6. 6. Duffy MJ, O'Grady P, Devaney D, O'Siorai L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 1988;62:531-3.
7. 7. Jänicke F, Schmitt M, Hafter R, Hollreider A, Babic R, Ulm K, et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990;4:69-78.
8. 8. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-12.
9. 9. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ. Urokinase plasminogen activator and prognosis in breast cancer. Lancet 1990;335:108.
10. 10. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
11. 11. Reilly D, Andreasen PA, Duffy MJ. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Blood Coagul Fibrinol 1991;2:47-50.
12. 12. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992;50:208-14.
13. 13. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74:2276-80.
14. 14. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
15. 15. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein 1996;49:85-93.
16. 16. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 1997;76:622-7.
17. 17. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O'Higgins. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998;44: 1177-83.
18. 18. Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989;334:1049.
19. 19. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
20. 20. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994;54:2527-30.
21. 21. Jänicke F, Thomssen C, Pache L, Schmitt M, Graeff H. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Hau J, editors. Prospects in Diagnosis and Treatment of Breast Cancer. Excerpta Medica International Congress Series. Amsterdam: Elsevier Publishers; 1994. p. 207-18.
22. 22. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997;76:306-11.
23. 23. Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, et al. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res 1999;18:2173-80.
24. 24. Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 1991;64:926-32.
25. 25. Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992;84:1266-72.
26. 26. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
27. 27. Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V, Oglobine J. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 1998;77:1495-501.
28. 28. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-5.
29. 29. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-58.
30. 30. Foekens JA, Schmitt M, Peters HA, Look MP, van Putten WLJ, Kramer MD, et al. Association of PAI-1 with metastasis-free survival in breast cancer: comparison with ER, PgR, PS2, cathepsin D and uPA. In: Schmitt M, Hau J, editors. Prospects in Diagnosis and Treatment of Breast Cancer. Excerpta Medica International Congress Series. Elsevier Publishers; 1994. p. 197-205.
31. 31. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995;55:1423-7.
32. 32. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995;87:751-6.
33. 33. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
34. 34. Foekens JA, Berns EMJJ, Look MP, Klijn JGM. Prognostic factors in node-negative breast cancer. In: Pasqualini JR, Katzenellebogen BS, editors. Hormone-Dependent Cancer. Marcel Decker, Inc; 1996. p. 217-53.
35. 35. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53:2513-21.
36. 36. Brünner N, Pyke C, Holst Hansen C, Rømer J, Grøndahl-Hansen J, Danø K. Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. In: Dickson R, Lippman M, editors. Mammary Tumorigenesis and malignant Progression. Kluwer Academic Publishers; 1994. p. 299-309.
37. 37. Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 1997;3:233-9.
38. 38. Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:153-63.
39. 39. Kute TE, Grøndahl-Hansen J, Shao S-M, Long R, Russell G, Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998;47:9-16.
40. 40. Yamashita J, Ogawa M, Yamashita S, Nikashima Y, Saishoji T, Nomura K, et al. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 1993;68:524-9.
41. 41. Yamashita J, Ogawa M, Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 1995;117:601-8.
42. 42. Fernö M, Bendahl P-O, Borg A, Brundell J, Hirschberg L, Olsson H, et al. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996;32A:793-801.
43. 43. Solomayer E-F, Diel IJ, Wallwiener D, Bode S, Meyberg G, Sillem M, et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 1997;76:812-8.
44. 44. Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998;4:177-82.
45. 45. Shiba E, Kim SJ, Taguchi T, Izukura M, Kobayashi T, Furukawa J, et al. A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol 1997;123:555-9.
46. 46. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm A-V, Simonsen ACW, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998;77:932-40.
47. 47. Peyrat J-P, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin Cancer Res 1998;4:189-96.
48. 48. Benraad ThJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJTM, de Witte JH, et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/Biomed-1 workshop. Eur J Cancer 1996;32A:1371-81.
49. 49. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJTM, Schmitt M, et al. External quality assessment of antigen determinations (ELISAs) of urokinase-type plasminogen activator and its type-1 inhibitor in extracts of human breast cancer tissue. Br J Cancer 1999; in press.
50. 50. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.